Halozyme Therapeutics, Inc. (ETR:RV7)

Market Cap	10.52B +47.4%
Revenue (ttm)	1.46B +41.2%
Net Income	362.02M -25.8%
EPS	2.96 -22.5%
Shares Out	n/a
PE Ratio	29.05
Forward PE	10.60
Dividend	n/a
Ex-Dividend Date	n/a

Volume	116
Open	90.00
Previous Close	91.60
Day's Range	90.00 - 92.70
52-Week Range	58.70 - 92.70
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 6, 2026

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) admini...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 423
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: RV7

Financial Performance

In 2025, Halozyme Therapeutics's revenue was $1.40 billion, an increase of 37.55% compared to the previous year's $1.02 billion. Earnings were $316.89 million, a decrease of -28.64%.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 24, 2026

Data Sources Report a data error